Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp. develops cancer screening and diagnostic tests used before, during, and after a cancer diagnosis. Company news centers on established products such as Cologuard and Oncotype DX, as well as newer diagnostics including Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease and recurrence monitoring.
Recurring updates include clinical data presentations in breast cancer and multi-cancer detection, policy and coverage developments for diagnostic testing, precision oncology product milestones, material agreements, shareholder voting matters, capital-structure disclosures, and operating and financial results.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Baird Global Healthcare Conference on September 9, 2020, at 2:00 p.m. EDT. Investors can join the event via webcast, accessible through the company's investor relations section on their website. Exact Sciences is a leader in cancer screening and diagnostic tests, known for innovations like Cologuard and Oncotype DX. The company is committed to advancing cancer care with ongoing investments in its product pipeline.
Exact Sciences Corp. (Nasdaq: EXAS) announces participation in the Canaccord Genuity Annual Growth Conference on August 12, 2020, at 2:30 p.m. EDT, inviting investors to join via webcast. The event aims to provide insights into the company's cancer screening and diagnostic innovations, including Cologuard and Oncotype DX. Exact Sciences is committed to improving patient care through ongoing product development and strategic partnerships, notably with Pfizer. The webcast will be accessible on their investor relations website.
Exact Sciences Corp. (Nasdaq: EXAS) reported a revenue of $268.9 million for Q2 2020, up from $199.9 million in Q2 2019. The company’s screening revenue fell 34% to $131.3 million, while Precision Oncology revenue reached $103.0 million. COVID-19 testing contributed $34.6 million. The gross margin stood at 63%, with a net loss of $86.1 million, or $0.58 per share. Despite challenges, the CEO highlighted the role of Cologuard in addressing missed cancer screenings during the pandemic.
Exact Sciences Corp. (Nasdaq: EXAS) announced its virtual annual stockholders meeting and second quarter 2020 earnings call. The meeting is scheduled for July 23, 2020, at 11 a.m. ET. The second quarter earnings release will occur on July 30, 2020, after U.S. market close, followed by a conference call at 5 p.m. ET. Investors can access the live webcasts and archives via the company's website. Exact Sciences focuses on cancer screening and diagnostics, with products like Cologuard and Oncotype DX.